Rhythm Pharmaceuticals COO Pamela Cramer Sells 1520 Shares at $85.93 Each on 2025-07-29.
ByAinvest
Tuesday, Jul 29, 2025 7:00 pm ET1min read
RYTM--
The transaction occurred amidst a period of market anticipation surrounding Rhythm Pharmaceuticals' upcoming earnings report, scheduled for release on August 5, 2025. Wall Street analysts expect the company to report a year-over-year decline in earnings, despite a significant increase in revenue [1].
The sale by Cramer, who holds a 10% ownership stake in the company, comes as analysts have recently revised their earnings estimates downward. The consensus estimate now projects a quarterly loss of $0.66 per share, representing a 20% year-over-year decrease. Revenue is expected to rise by 49.3% to $43.41 million [1].
The Earnings ESP (Expected Surprise Prediction) model, developed by Zacks Investment Research, indicates a negative ESP of -9.85% for Rhythm Pharmaceuticals. This suggests that analysts have become more bearish on the company's earnings prospects. The Zacks Rank of #3 for the stock makes it difficult to predict an earnings beat, although the company has a history of beating estimates in the past [1].
Investors should monitor the upcoming earnings report and other factors influencing the stock's performance. While the sale by Cramer may indicate a shift in sentiment, it is essential to consider the broader market conditions and the company's earnings trajectory.
References:
[1] https://www.nasdaq.com/articles/earnings-preview-rhythm-pharmaceuticals-inc-rytm-q2-earnings-expected-decline
[2] https://www.streetinsider.com/SEC+Filings/Form+4+RHYTHM+PHARMACEUTICALS%2C+For%3A+Jul+26+Filed+by%3A+Cramer+Pamela+J./25116049.html
Rhythm Pharmaceuticals, Inc. (RYTM) announced that Chief Human Resources Officer Pamela J. Cramer has sold 1,520 shares at $85.93 per share on July 29, 2025.
Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company, reported that its Chief Human Resources Officer, Pamela J. Cramer, sold 1,520 shares of the company's common stock on July 29, 2025. The sale was executed at $85.93 per share [2].The transaction occurred amidst a period of market anticipation surrounding Rhythm Pharmaceuticals' upcoming earnings report, scheduled for release on August 5, 2025. Wall Street analysts expect the company to report a year-over-year decline in earnings, despite a significant increase in revenue [1].
The sale by Cramer, who holds a 10% ownership stake in the company, comes as analysts have recently revised their earnings estimates downward. The consensus estimate now projects a quarterly loss of $0.66 per share, representing a 20% year-over-year decrease. Revenue is expected to rise by 49.3% to $43.41 million [1].
The Earnings ESP (Expected Surprise Prediction) model, developed by Zacks Investment Research, indicates a negative ESP of -9.85% for Rhythm Pharmaceuticals. This suggests that analysts have become more bearish on the company's earnings prospects. The Zacks Rank of #3 for the stock makes it difficult to predict an earnings beat, although the company has a history of beating estimates in the past [1].
Investors should monitor the upcoming earnings report and other factors influencing the stock's performance. While the sale by Cramer may indicate a shift in sentiment, it is essential to consider the broader market conditions and the company's earnings trajectory.
References:
[1] https://www.nasdaq.com/articles/earnings-preview-rhythm-pharmaceuticals-inc-rytm-q2-earnings-expected-decline
[2] https://www.streetinsider.com/SEC+Filings/Form+4+RHYTHM+PHARMACEUTICALS%2C+For%3A+Jul+26+Filed+by%3A+Cramer+Pamela+J./25116049.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet